Pesquisa | Biblioteca Virtual em Saúde

1.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic, Vlado; Jardine, Meg J; Neal, Bruce; Bompoint, Severine; Heerspink, Hiddo J L; Charytan, David M; Edwards, Robert; Agarwal, Rajiv; Bakris, George; Bull, Scott; Cannon, Christopher P; Capuano, George; Chu, Pei-Ling; de Zeeuw, Dick; Greene, Tom; Levin, Adeera; Pollock, Carol; Wheeler, David C; Yavin, Yshai; Zhang, Hong; Zinman, Bernard; Meininger, Gary; Brenner, Barry M; Mahaffey, Kenneth W.

N Engl J Med; 380(24): 2295-2306, 2019 06 13.

Artigo em Inglês | MEDLINE | ID: mdl-30990260

2.

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.

Cannon, Christopher P; Perkovic, Vlado; Agarwal, Rajiv; Baldassarre, James; Bakris, George; Charytan, David M; de Zeeuw, Dick; Edwards, Robert; Greene, Tom; Heerspink, Hiddo J L; Jardine, Meg J; Levin, Adeera; Li, Jing-Wei; Neal, Bruce; Pollock, Carol; Wheeler, David C; Zhang, Hong; Zinman, Bernard; Mahaffey, Kenneth W.

Circulation; 2019 Nov 11.

Artigo em Inglês | MEDLINE | ID: mdl-31707795

3.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.

Mahaffey, Kenneth W; Jardine, Meg J; Bompoint, Severine; Cannon, Christopher P; Neal, Bruce; Heerspink, Hiddo J L; Charytan, David M; Edwards, Robert; Agarwal, Rajiv; Bakris, George; Bull, Scott; Capuano, George; de Zeeuw, Dick; Greene, Tom; Levin, Adeera; Pollock, Carol; Sun, Tao; Wheeler, David C; Yavin, Yshai; Zhang, Hong; Zinman, Bernard; Rosenthal, Norman; Brenner, Barry M; Perkovic, Vlado.

Circulation; 140(9): 739-750, 2019 Aug 27.

Artigo em Inglês | MEDLINE | ID: mdl-31291786

4.

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.

Agarwal, Rajiv; Rossignol, Patrick; Romero, Alain; Garza, Dahlia; Mayo, Martha R; Warren, Suzette; Ma, Jia; White, William B; Williams, Bryan.

Lancet; 394(10208): 1540-1550, 2019 10 26.

Artigo em Inglês | MEDLINE | ID: mdl-31533906

5.

Understanding the Right to Try Act.

Agarwal, Rajiv; Saltz, Leonard B.

Clin Cancer Res; 2019 Oct 30.

Artigo em Inglês | MEDLINE | ID: mdl-31666248

6.

Caring for individuals with hypertension in CKD, especially those with low education.

Agarwal, Rajiv.

Kidney Int; 96(4): 820-822, 2019 Oct.

Artigo em Inglês | MEDLINE | ID: mdl-31543151

7.

Optimal management of gastroesophageal junction cancer.

Greally, Megan; Agarwal, Rajiv; Ilson, David H.

Cancer; 125(12): 1990-2001, 2019 Jun 15.

Artigo em Inglês | MEDLINE | ID: mdl-30973648

8.

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline.

Kramer, Holly J; Townsend, Raymond R; Griffin, Karen; Flynn, Joseph T; Weiner, Daniel E; Rocco, Michael V; Choi, Michael J; Weir, Matthew R; Chang, Tara I; Agarwal, Rajiv; Beddhu, Srinivasan.

Am J Kidney Dis; 73(4): 437-458, 2019 Apr.

Artigo em Inglês | MEDLINE | ID: mdl-30905361

9.

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.

Bakris, George L; Agarwal, Rajiv; Anker, Stefan D; Pitt, Bertram; Ruilope, Luis M; Nowack, Christina; Kolkhof, Peter; Ferreira, Anna C; Schloemer, Patrick; Filippatos, Gerasimos.

Am J Nephrol; 50(5): 333-344, 2019.

Artigo em Inglês | MEDLINE | ID: mdl-31655812

10.

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.

Ruilope, Luis M; Agarwal, Rajiv; Anker, Stefan D; Bakris, George L; Filippatos, Gerasimos; Nowack, Christina; Kolkhof, Peter; Joseph, Amer; Mentenich, Nicole; Pitt, Bertram.

Am J Nephrol; 50(5): 345-356, 2019.

Artigo em Inglês | MEDLINE | ID: mdl-31665733

11.

A longitudinal study of the effects of age, sex and race on body composition in chronic kidney disease.

Agarwal, Rajiv.

Nephrol Dial Transplant; 2019 Mar 07.

Artigo em Inglês | MEDLINE | ID: mdl-30844075

12.

Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, ß-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.

Ferreira, João Pedro; Couchoud, Cécile; Gregson, John; Tiple, Aurélien; Glowacki, François; London, Gerard; Agarwal, Rajiv; Rossignol, Patrick.

Nephrol Dial Transplant; 34(7): 1216-1222, 2019 Jul 01.

Artigo em Inglês | MEDLINE | ID: mdl-30590716

13.

Systolic and diastolic hypertension among patients on hemodialysis: Musings on volume overload, arterial stiffness, and erythropoietin.

Georgianos, Panagiotis I; Agarwal, Rajiv.

Semin Dial; 32(6): 507-512, 2019 Nov.

Artigo em Inglês | MEDLINE | ID: mdl-31463996

14.

A mixed methods analysis of patients' advance care planning values in outpatient oncology: Person-Centered Oncologic Care and Choices (P-COCC).

Agarwal, Rajiv; Shuk, Elyse; Romano, Danielle; Genoff, Margaux; Li, Yuelin; O'Reilly, Eileen M; Breitbart, William; Volandes, Angelo E; Epstein, Andrew S.

Support Care Cancer; 2019 Jun 13.

Artigo em Inglês | MEDLINE | ID: mdl-31197540

15.

Minimally sufficient numbers of measurements for validation of 24-hour blood pressure monitoring in chronic kidney disease.

Agarwal, Rajiv; Tu, Wanzhu.

Kidney Int; 94(6): 1199-1204, 2018 Dec.

Artigo em Inglês | MEDLINE | ID: mdl-30385040

16.

Revisiting RAAS blockade in CKD with newer potassium-binding drugs.

Georgianos, Panagiotis I; Agarwal, Rajiv.

Kidney Int; 93(2): 325-334, 2018 02.

Artigo em Inglês | MEDLINE | ID: mdl-29276100

17.

Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.

Agarwal, Rajiv; Rossignol, Patrick; Garza, Dahlia; Mayo, Martha R; Warren, Suzette; Arthur, Susan; Romero, Alain; White, William B; Williams, Bryan.

Am J Nephrol; 48(3): 172-180, 2018.

Artigo em Inglês | MEDLINE | ID: mdl-30176673

18.

Mechanisms and mediators of hypertension induced by erythropoietin and related molecules.

Agarwal, Rajiv.

Nephrol Dial Transplant; 33(10): 1690-1698, 2018 Oct 01.

Artigo em Inglês | MEDLINE | ID: mdl-29228345

19.

Feeding during dialysis-risks and uncertainties.

Agarwal, Rajiv; Georgianos, Panagiotis.

Nephrol Dial Transplant; 33(6): 917-922, 2018 Jun 01.

Artigo em Inglês | MEDLINE | ID: mdl-28633456

20.

Glomerular filtration rate: when to measure and in which patients?

Agarwal, Rajiv; Delanaye, Pierre.

Nephrol Dial Transplant; 2018 Dec 06.

Artigo em Inglês | MEDLINE | ID: mdl-30520986

Biblioteca Virtual em Saúde

Brasil

Sua seleção (0)

Formato de exportação:

Exportar:

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.

Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial.

Understanding the Right to Try Act.

Caring for individuals with hypertension in CKD, especially those with low education.

Optimal management of gastroesophageal junction cancer.

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline.

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.

Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.

A longitudinal study of the effects of age, sex and race on body composition in chronic kidney disease.

Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, ß-blockers or both in incident end-stage renal disease patients without cardiovascular disease: a propensity-matched longitudinal cohort study.

Systolic and diastolic hypertension among patients on hemodialysis: Musings on volume overload, arterial stiffness, and erythropoietin.

A mixed methods analysis of patients' advance care planning values in outpatient oncology: Person-Centered Oncologic Care and Choices (P-COCC).

Minimally sufficient numbers of measurements for validation of 24-hour blood pressure monitoring in chronic kidney disease.

Revisiting RAAS blockade in CKD with newer potassium-binding drugs.

Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.

Mechanisms and mediators of hypertension induced by erythropoietin and related molecules.

Feeding during dialysis-risks and uncertainties.

Glomerular filtration rate: when to measure and in which patients?